A new trading day began on Friday, with Kymera Therapeutics Inc (NASDAQ: KYMR) stock price up 0.79% from the previous day of trading, before settling in for the closing price of $40.29. KYMR’s price has ranged from $26.34 to $53.27 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 301.53%. Meanwhile, its annual earnings per share averaged -11.95%. With a float of $54.99 million, this company’s outstanding shares have now reached $64.75 million.
The extent of productivity of a business whose workforce counts for 187 workers is very important to gauge. In terms of profitability, gross margin is 92.85%, operating margin of -223.0%, and the pretax margin is -191.26%.
Kymera Therapeutics Inc (KYMR) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Kymera Therapeutics Inc is 15.09%, while institutional ownership is 93.76%. The most recent insider transaction that took place on Jan 06 ’25, was worth 130,645. In this transaction Chief Legal Officer of this company sold 3,129 shares at a rate of $41.75, taking the stock ownership to the 54,826 shares. Before that another transaction happened on Jan 06 ’25, when Company’s Officer proposed sale 3,129 for $41.59, making the entire transaction worth $130,135.
Kymera Therapeutics Inc (KYMR) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.75 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -11.95% per share during the next fiscal year.
Kymera Therapeutics Inc (NASDAQ: KYMR) Trading Performance Indicators
Here are Kymera Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 8.55. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 30.04.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.33, a number that is poised to hit -0.77 in the next quarter and is forecasted to reach -3.06 in one year’s time.
Technical Analysis of Kymera Therapeutics Inc (KYMR)
The latest stats from [Kymera Therapeutics Inc, KYMR] show that its last 5-days average volume of 0.67 million was superior to 0.55 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 67.46%. Additionally, its Average True Range was 2.77.
During the past 100 days, Kymera Therapeutics Inc’s (KYMR) raw stochastic average was set at 28.47%, which indicates a significant decrease from 57.47% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 71.93% in the past 14 days, which was higher than the 54.41% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $43.63, while its 200-day Moving Average is $41.32. Now, the first resistance to watch is $41.51. This is followed by the second major resistance level at $42.41. The third major resistance level sits at $42.92. If the price goes on to break the first support level at $40.09, it is likely to go to the next support level at $39.58. The third support level lies at $38.68 if the price breaches the second support level.
Kymera Therapeutics Inc (NASDAQ: KYMR) Key Stats
With a market capitalization of 2.63 billion, the company has a total of 64,765K Shares Outstanding. Currently, annual sales are 78,590 K while annual income is -146,960 K. The company’s previous quarter sales were 3,740 K while its latest quarter income was -62,490 K.
